Rituximab biosimilar - International Biotech Center Generium

Drug Profile

Rituximab biosimilar - International Biotech Center Generium

Alternative Names: Deplera; GNR-006

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator International Biotech Center Generium
  • Developer International Biotechnology Center Generium
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I B cell lymphoma

Most Recent Events

  • 28 Feb 2018 Phase-I clinical trials in B-cell lymphoma in Russia (Parenteral) before February 2018 (Ligand Pharmaceuticals pipeline, April 2018)
  • 26 Oct 2015 Preclinical trials in B-cell lymphoma in Russia (Parenteral) before October 2015
  • 26 Oct 2015 Russian regulatory authority approves IND application for GNR 006 in B-cell lymphoma (Generium's website, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top